Recently added

Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial

Eng, Cathy; Kim, Tae Won; Wasan, Harpreet; Kopetz, Scott; Yoshino, Takayuki; Van Cutsem, Eric; Tabernero, Josep (Nature Portfolio, 2025-03)

First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-305

Moehler, Markus; Lee, Keun-Wook; OH, DO-YOUN; Kato, Ken; Arkenau, Hendrik-Tobias; Tabernero, Josep (Adis, 2025-05)

Reporting of molecular test results from cell-free DNA analyses: expert consensus recommendations from the 2023 European Liquid Biopsy Society ctDNA Workshop

de Jager, Vincent D.; Giacomini, Patrizio; Fairley, Jennifer A.; Patton, Simon; Joosse, Simon A.; Toledo, Rodrigo (Elsevier, 2025-04)

Oncology professionals' perceptions and recommendations to improve well-being and health at work in times of crisis: qualitative thematic analysis from the ESMO Resilience Task Force survey series

Thorne, Eleanor; O'Connor, Miriam; Elez, Elena; Hardy, Claire; KAMPOSIORAS, KONSTANTNOS; Punie, Kevin (Elsevier, 2025-03)

Identifying germline pathogenic variants in breast cancer using tumor sequencing

Papakonstantinou, Andri; Castillo, Ester; Vega Cano, Kreina Sharela; Torres López, Maite; Moles-Fernández, Alejandro; Cruellas , Mara; Lopez-Fernandez, Adrià; Matito, Judit; Gómez-Rey, Marina; Rezqallah Arón , María Alejandra; Saura Manich, Cristina; Vivancos, Ana; Balmaña, Judith; Oliveira, Mafalda; Navarro Garces, Victor (Elsevier, 2025-06)

Scientia. Department of Health Digital Information Depot

VHIO - Articles científics: Recent submissions

Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial

First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-305

Reporting of molecular test results from cell-free DNA analyses: expert consensus recommendations from the 2023 European Liquid Biopsy Society ctDNA Workshop

Oncology professionals' perceptions and recommendations to improve well-being and health at work in times of crisis: qualitative thematic analysis from the ESMO Resilience Task Force survey series

Identifying germline pathogenic variants in breast cancer using tumor sequencing

Scientia. Department of Health Digital Information Depot

VHIO - Articles científics: Recent submissions

Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial ﻿

First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-305 ﻿

Reporting of molecular test results from cell-free DNA analyses: expert consensus recommendations from the 2023 European Liquid Biopsy Society ctDNA Workshop ﻿

Oncology professionals' perceptions and recommendations to improve well-being and health at work in times of crisis: qualitative thematic analysis from the ESMO Resilience Task Force survey series ﻿

Identifying germline pathogenic variants in breast cancer using tumor sequencing ﻿

Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial

First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-305

Reporting of molecular test results from cell-free DNA analyses: expert consensus recommendations from the 2023 European Liquid Biopsy Society ctDNA Workshop

Oncology professionals' perceptions and recommendations to improve well-being and health at work in times of crisis: qualitative thematic analysis from the ESMO Resilience Task Force survey series

Identifying germline pathogenic variants in breast cancer using tumor sequencing